Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Spectral's Pivotal year (2024)

<< Previous

Bullboard Posts

Next >>

Comment by gebremeskelon Jun 03, 2024 12:39pm

93 Views

Post# 36069529

RE:Spectral's Pivotal year (2024)

Thanks for that informative post mercedesman.

mercedesman wrote: There are 11.1M .50 warrants that expire July 27, 2024. They are currently JUST out of the money , but only by 1 red cent (.49 vs. .50) . If fully exercised, those warrants would bring in another $5.6M in cash !!!

A couple of Directors are already jumping the gun on this (WUWT?).

Can you say "possibly/likely fully funded" until the point at which the FDA rules on PMX post-Trial completion?

Two more points:

that's if they need $ for that long (see Vantive H2 announcement plans)

The FDA granted Breakthrough Device Designation (BDD) in 2022 which theoretically shortens the pathway to commercialization.

"We continue to see 2024 as a pivotal year for the company" Scott McAuley

MM